Yushuda Tablets

The reduction of HAMD17 total score after 8 weeks of treatment compared with the baseline was used as the primary efficacy indicator. A randomized, double-blind, placebo-controlled, multicenter clinical trial design was used to evaluate the efficacy and safety of Yushuda Tablets in the treatment of mild to moderate depression (dampness and turbidity obstructing the spleen, qi stagnation syndrome).